Searched for
CRESTOR
AstraZeneca India recasts biopharma unitAstraZeneca India has laid off over 125 employees in its biopharmaceutical business unit, including senior managers and sales executives. T...- AstraZeneca sells cholesterol drug rights to Grünenthal for $320 millionAstraZeneca, which is among the front-runners in the race to develop a vaccine for the novel coronavirus, has been trying to focus on its c...
- Cadila Healthcare gains on USFDA nod for memory loss drugThe group now has 252 approvals and has so far filed over 350 ANDAs since the commencement of the filing process in FY 2003-04.
- Pricing pressure in US to keep pharma companies' growth under checkDr Reddy's Lab is expected to report subdued numbers in 3QFY17, with revenue declining 6.1 per cent Y-o-Y to Rs 37.2 billion and PAT down 2...
- Top 2 stock picks in pharma and IT: Daljeet Singh Kohli, IndiaNiveshAmong top tier companies, we are pushing on Lupin, Torrent among midcaps, Aurobindo and among smaller ones Shilpa Medicare and Ajanta Pharma
- Sensex ends 128 points higher, Nifty50 above 8,550 as CIL surges 3%Elsewhere, most other Asian markets closed mixed. Japan’s Nikkei closed with losses of 0.25 per cent after Nintendo shares took a dive, but...
- Sun Pharma gets FDA nod for rosuvastatin calcium tabletsSun Pharma said: "One of its subsidiaries has received final approval from USFDA for its Abbreviated New Drug Application (ANDA) for generi...
- Aurobindo Pharma gets FDA nod for rosuvastatin calcium tabsAurobindo Pharma has received final approval from the US health regulator USFDA for rosuvastatin calcium tablets, used in lowering choleste...
- Glenmark gets FDA nod for rosuvastatin calcium tabletsQuoting IMS sales data for the 12 months to May 2016, Glenmark said Rosuvastatin calcium tablets achieved annual sales of around USD 6.78 b...
- Top five wealth creating ideas from 3 top global brokeragesMacroeconomic data shows green shoots in the economy. India’s recent GDP growth number at 7.9% for Q4FY'16 was largely driven by private co...
- Outperform on Torrent Pharma, target Rs 1500: Credit SuisseThe brokerage firm said that it stays positive due to high contribution of high-return India formulations
- Europe approves Biocon's Rosuvastatin Calcium tabletsThe approval in the regulated markets marks an important milestone in Biocon's small molecules strategy of forward integration from APIs.
- New US norms on statins to help Indian drug firmsCholesterol-reducing drugs worth nearly $15 billion (Rs 92,000 crore) were sold in the US in the year to September 2013, Bakhru wrote in hi...
- AstraZeneca settles Crestor patent row with generics firmsAstraZeneca settleS a legal fight over its top-selling cholesterol drug Crestor with generics companies, protecting revenues in all importa...
- Ranbaxy labs gets Health Canada nod for cholesterol lowering drugRanbaxy Labs said it has received approval from the Health Canada to manufacture & mkt its generic RAN-Rosuvastatin tablets used for loweri...
- Aurobindo gets USFDA's tentative nod for CrestorAurobindo Pharma said it has received tentative approval of the USFDA for the generic version of Crestor tablets used in the cardiovascular...
- AstraZeneca first-quarter profit up 42 pcAstraZeneca posted a 42 per cent rise in first quarter net profit on Thursday, boosted by sales of its heart drug Toprol-XL in the United S...
- AstraZeneca India announces CRESTOR tablets launchAstraZeneca India announced the launch of CRESTOR® (rosuvastatin) 5, 10, 20 and 40 mg tablets. CRESTOR® is indicated for use in the treatme...
- AstraZeneca plans to double job cutsAstraZeneca PLC said it will more than double previously planned job cuts as it revealed Thursday that quarterly profit fell 12.5 per cent.
- Cholesterol drugmakers brace for competitionThe makers of cholesterol drugs are promoting their products ahead of a major change that is expected to trigger more competition in the ma...
Load More
